2017, Number 2
<< Back Next >>
Anales de Radiología México 2017; 16 (2)
Soft transcatheter embolization of hepatocellular carcinoma
Salinas-Sepúlveda JH, Carrillo-Martínez MA
Language: Spanish
References: 18
Page: 122-128
PDF size: 237.53 Kb.
ABSTRACT
Objetive: evaluate the survival of patients with diagnosis of hepatocellular carcinoma, treated with soft transcatheter arterial embolization at Hospital San José Tecnológico de Monterrey from January 2007 through September 2013.
Method: we conducted a retrospective study of long-term results in survival of patients with hepatocellular carcinoma treated with soft transcatheter arterial embolization at Hospital San Jose del Tecnologico de Monterrey in the period from January 2007 through September 2013. The information was obtained from clinical records and image files. We conducted analyses with Kaplan Meier curves and univariate and multivariate regressions with Cox regressions of factors that could influence the prognosis.
Results: we identified 30 patients who complied with the study screening criteria. We determined a general survival with a mean of 19.3 months and probabilities of survival at one year, two years, and three years of 66.7, 30.2, and 16.8%, respectively. The variables of hepatic function and localization of treated territory were significant as prognosis factors in the univariate and multivariate analyses.
Conclusion: the results obtained in survival of patients treated with soft transcatheter arterial embolization are similar to those reported in the worldwide specialized literature.
REFERENCES
INEGI (2013) “Estadísticas a propósito del día mundial contra el cáncer”.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T y cols: Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
Bruix J, Sherman M, Llovet JM y cols: Clinical management of hepatocellu- lar carcinoma. Conclusions of the Barcelona 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-S188.
Cabibbo G, Enea M, Attanasio y cols : A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274-1283.
Hoshida Y, Villanueva A, Kobayashi M y cols: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med2008, 359:1995–2004.
Maluccio M, Covey A, Porat L y cols: Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2008;19: 862-869.
Lo, C., Ngan, H., & Tso, W: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35(5):1164- 1171.
Yau, T., Tang, V., Yao y cols: Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014;146(7):1691-170. Figura 3. Función de supervivencia acumulada por localización de las lesiones.
INEGI (2013) “Estadísticas a propósito del día mundial contra el cáncer”.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T y cols: Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
Bruix J, Sherman M, Llovet JM y cols: Clinical management of hepatocellu- lar carcinoma. Conclusions of the Barcelona 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-S188.
Cabibbo G, Enea M, Attanasio y cols : A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274-1283.
Hoshida Y, Villanueva A, Kobayashi M y cols: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med2008, 359:1995–2004.
Maluccio M, Covey A, Porat L y cols: Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2008;19: 862-869.
Lo, C., Ngan, H., & Tso, W: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35(5):1164- 1171.
Yau, T., Tang, V., Yao y cols: Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014;146(7):1691-170. Figura 3. Función de supervivencia acumulada por localización de las lesiones.
Full text